Drug Description in Trials / DrugBank / KEGG DRUG

  

Search results

No. 薬物名（臨床試験情報から抽出） DrugBank KEGG DRUG KEGG GENES KEGG PATHWAY 指定難病告示番号
1Irbesartan tablets (NDC# 43547-0374-03 and NDC 43547-374-09, approved in the USA) Generic tablets distributed by Solco Healthcare US, LLCProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tablets (NDC# 31722-729-30 approved in the United states)Product Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021O1件: Irbesartan1件: Irbesartan 💬 1件: AGTR1 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
2Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-1件: Irbesartan1件: Irbesartan 💬 1件: AGTR1 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
3Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-1件: Irbesartan1件: Irbesartan 💬 1件: AGTR1 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
4Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Trade Name: Irbesartan tabletsProduct Name: over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-Trade Name: Irbesartan tabletsProduct Name: Over-encapsulated Irbesartan TabletsPharmaceutical Form: Capsule, hardINN or Proposed INN: IrbesartanCAS Number: 138402-11-6Other descriptive name: IRBESARTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 75-Product Name: SparsentanProduct Code: RE-021Pharmaceutical Form: TabletINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 400-1件: Irbesartan1件: Irbesartan 💬 1件: AGTR1 💬 17件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cGMP-PKG signaling pathway 💬1件: 222 💬
5RE-021 (Sparsentan)1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
6SPARSENTAN1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬4件: 66, 218, 222, 223 💬
7Sparsentan compresse1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 66 💬
8Sparsentan tablets/Over-encapsulated Sparsentan tablets1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 66 💬
9Sparsentan tablets/over-encapsulated Spasenten tablets1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 66 💬
10Sparsentan tablets/Overencapsulated Sparsentan tablets1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 66 💬
11Sparsentan/Over-encapsulated Sparsentan tablet1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
12Sparsentan/Over-encapsulated Sparsentan tabletProduct Code: RE-021Pharmaceutical Form: Capsule, hardINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
13Sparsentan/Over-encapsulated Sparsentan tablets1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
14Sparsentan/Over-encapsulated Sparsentan tabletsProduct Code: RE-021Pharmaceutical Form: Capsule, hardCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
15Sparsentan/Over-encapsulated Sparsentan tabletsProduct Code: RE-021Pharmaceutical Form: Capsule, hardINN or Proposed INN: SparsentanCAS Number: 254740-64-2Concentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
16Sparsentan/Over-encapsulated Sparsentan tabletsProduct Code: RE-021Pharmaceutical Form: Capsule, hardINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-1件: Sparsentan (Sparsentan)1件: Sparsentan (Sparsentan) 💬 2件: AGTR1,
EDNRA 💬 		18件: AGE-RAGE signaling pathway in diabetic complications, Adrenergic signaling in cardiomyocytes, Aldosterone synthesis and secretion, Apelin signaling pathway, Calcium signaling pathway, Coronavirus disease, Cortisol synthesis and secretion, Cushing syndrome, Diabetic cardiomyopathy, Hormone signaling, Neuroactive ligand-receptor interaction, Pathways in cancer, Phospholipase D signaling pathway, Renin secretion, Renin-angiotensin system, Vascular smooth muscle contraction, cAMP signaling pathway, cGMP-PKG signaling pathway 💬1件: 222 💬
17SparsentanProduct Code: RE-021Pharmaceutical Form: Capsule, hardINN or Proposed INN: SparsentanCAS Number: 254740-64-2Current Sponsor code: RE-021Other descriptive name: SPARSENTANConcentration unit: mg milligram(s)Concentration type: equalConcentration number: 200-----1件: 222 💬